#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14126	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2157	650.8	0	.	n	.	0	C1450T	SNP	1450	1450	C	1719	1719	T	835	T,C	757,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14126	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2157	650.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1453	1453	C	848	C	777	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26064	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3706	701.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1767	1767	A	870	A,G	793,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26064	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3706	701.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2401	2401	C	861	C,T	790,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26064	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3706	701.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2475	2475	A	874	A	806	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26064	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3706	701.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	3027	3027	C	797	C	742	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2008	folP	855	855	100.0	folP.l15.c4.ctg.1	1540	129.5	1	SNP	p	R229S	1	.	.	685	687	AGC	1058	1060	AGC	212;210;211	A;G;C	201;200;199	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5314	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3463	152.9	1	SNP	p	S91F	1	.	.	271	273	TTC	619	621	TTC	172;173;174	T;T;C	160;160;163	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5314	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3463	152.9	1	SNP	p	D95G	1	.	.	283	285	GGC	631	633	GGC	175;178;177	G;G;C	160;159;157	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5314	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3463	152.9	1	SNP	p	G95N	0	.	.	283	285	GGC	631	633	GGC	175;178;177	G;G;C	160;159;157	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1690	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1335	125.8	1	SNP	p	G45D	0	.	.	133	135	GGC	418	420	GGC	218;217;220	G;G;C,A	198;198;199,1	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	844	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1049	79.7	0	.	n	.	0	A197.	DEL	197	197	A	600	600	A	215	A	199	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4764	parC	2304	2304	99.87	parC.l15.c30.ctg.1	2750	171.8	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1372	1374	GTC	201;202;203	G;T;C	171;173;174	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4764	parC	2304	2304	99.87	parC.l15.c30.ctg.1	2750	171.8	1	SNP	p	D86N	0	.	.	256	258	GAC	478	480	GAC	188;192;194	G;A,G;C	173;176,1;181	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4764	parC	2304	2304	99.87	parC.l15.c30.ctg.1	2750	171.8	1	SNP	p	R87W	0	.	.	259	261	CGT	481	483	CGT	198;202;201	C;G;T	181;186;183	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4764	parC	2304	2304	99.87	parC.l15.c30.ctg.1	2750	171.8	1	SNP	p	S87R	1	.	.	259	261	CGT	481	483	CGT	198;202;201	C;G;T	181;186;183	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4764	parC	2304	2304	99.87	parC.l15.c30.ctg.1	2750	171.8	1	SNP	p	R87I	0	.	.	259	261	CGT	481	483	CGT	198;202;201	C;G;T	181;186;183	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4764	parC	2304	2304	99.87	parC.l15.c30.ctg.1	2750	171.8	1	SNP	p	S88P	0	.	.	262	264	TCC	484	486	TCC	203;205;206	T;C;C	186;185;188	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4504	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2468	181.1	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1259	1261	TGC	224;224;229	T;G;C	208;206;211	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4504	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2468	181.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1469	1471	GGC	222;219;223	G,T;G,T;C	202,1;200,1;200	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	3768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	152.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1243	1245	GCA	203;202;200	G;C;A	185;185;186	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	152.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1246	1248	ATC	201;201;201	A,G;T;C	187,1;187;189	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	152.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1258	1260	GTG	209;208;209	G;T;G	192;189;190	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	152.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1258	1260	GTG	209;208;209	G;T;G	192;189;190	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	152.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1762	1764	ACC	201;198;195	A;C;C	177;179;178	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	152.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1816	1818	GCG	174;172;172	G;C;G	152;135;144	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	152.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1816	1818	GCG	174;172;172	G;C;G	152;135;144	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	152.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1939	1941	GGC	179;180;180	G;G,T;C	161;162,1;165	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	152.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1948	1950	GGC	177;178;177	G;G;C	157;159;157	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2460	152.8	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1966	1968	TCG	179;181;182	T,G;C,G;G	118,6;140,1;147	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5746	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3087	185.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1590	1592	CCG	214;215;217	C;C;G,C	188;194;184,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2404	porA	1146	1146	99.56	porA.l6.c4.ctg.1	1721	138.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	555	555	C	177	C	161	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2544	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1446	174.1	0	.	p	.	0	N38E	NONSYN	112	114	AAT	371	373	GAA	219;218;215	G;A;A	202;204;199	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2544	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1446	174.1	0	.	p	.	0	N134D	NONSYN	400	402	AAT	659	661	GAT	220;221;220	G;A;T	190;193;191	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2544	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1446	174.1	0	.	p	.	0	P175S	NONSYN	523	525	CCA	782	784	TCA	209;209;209	T;C;A	191;188;189	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2544	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1446	174.1	0	.	p	.	0	A218V	NONSYN	652	654	GCC	911	913	GTC	210;208;210	G,C;T,C;C	190,1;190,1;191	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2544	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1446	174.1	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1241	1243	GCA	203;204;205	G;C;A	183;183;185	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2544	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1446	174.1	1	SNP	p	G120K	1	.	.	358	360	AAG	617	619	AAG	211;208;208	A;A;G	191;191;190	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2544	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1446	174.1	1	SNP	p	D121N	0	.	.	361	363	GAC	620	622	GAC	205;205;205	G;A;C	187;189;188	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2544	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1446	174.1	1	SNP	p	A121D	1	.	.	361	363	GAC	620	622	GAC	205;205;205	G;A;C	187;189;188	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10276	rpoB	4179	4179	100.0	rpoB.l6.c30.ctg.1	4829	212.2	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1998	2000	AAT	213;213;214	A;A;T,C	194;195;196,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1068	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1037	102.4	1	SNP	p	V57M	1	.	.	169	171	ATG	522	524	ATG	224;223;223	A;T;G	206;206;205	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
